Literature DB >> 23450103

Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates.

N Nicolaou1, Y Agrawal, M Padman, J A Fernandes, M J Bell.   

Abstract

PURPOSE: Osteogenesis imperfecta (OI) has been treated with bisphosphonates for many years, with some clear clinical benefits. In adults, there are reports of a new pattern of atraumatic subtrochanteric fractures with bisphosphonate treatment. This study assesses if bisphosphonate treatment leads to an altered pattern of femoral fractures.
METHODS: Retrospective review of imaging for a cohort of 176 bisphosphonate-treated OI patients to identify the locations of femoral fractures over a two-year period, as compared to a historical control group managed pre-bisphosphonates.
RESULTS: Sixteen femoral fractures were identified in this time period in the bisphosphonate-treated group. All but two were within the subtrochanteric region. In comparison, the historical group-composed of 26 femoral fractures-had a more widespread fracture pattern, with the most frequent location being the mid-diaphysis. Many of the subtrochanteric fractures in the treatment group occurred with minimal trauma.
CONCLUSIONS: It appears that concerns over the treatment of the adult osteoporotic population with bisphosphonates are amplified and mirrored in OI. It is possible that the high bending moments in the proximal femur together with altered mechanical properties of cortical bone secondary to the use of this group of drugs increase the risk of this type of injury, which warrants further modification of surgical management of the femur.

Entities:  

Keywords:  Bisphosphonates; Osteogenesis imperfecta

Year:  2012        PMID: 23450103      PMCID: PMC3303010          DOI: 10.1007/s11832-011-0380-0

Source DB:  PubMed          Journal:  J Child Orthop        ISSN: 1863-2521            Impact factor:   1.548


  53 in total

1.  A rational approach to management of alendronate-related subtrochanteric fractures.

Authors:  S Das De; T Setiobudi; L Shen; S Das De
Journal:  J Bone Joint Surg Br       Date:  2010-05

2.  Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.

Authors:  Davide Gatti; Franco Antoniazzi; Rosangela Prizzi; Vania Braga; Maurizio Rossini; Luciano Tatò; Ombretta Viapiana; Silvano Adami
Journal:  J Bone Miner Res       Date:  2004-12-20       Impact factor: 6.741

3.  Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.

Authors:  Elisabeth J Smith; David G Little; Julie N Briody; Anthony McEvoy; Nicholas C Smith; John A Eisman; Edith M Gardiner
Journal:  J Bone Miner Res       Date:  2005-06-13       Impact factor: 6.741

4.  Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.

Authors:  H Plotkin; F Rauch; N J Bishop; K Montpetit; J Ruck-Gibis; R Travers; F H Glorieux
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

5.  Density and architecture have greater effects on the toughness of trabecular bone than damage.

Authors:  Jacqueline G Garrison; Constance L Slaboch; Glen L Niebur
Journal:  Bone       Date:  2009-01-14       Impact factor: 4.398

6.  Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats.

Authors:  Mohammad Shahnazari; Wei Yao; WeiWei Dai; Bob Wang; Sophi S Ionova-Martin; Robert O Ritchie; Daniel Heeren; Andrew J Burghardt; Daniel P Nicolella; Michael G Kimiecik; Nancy E Lane
Journal:  Bone       Date:  2009-11-26       Impact factor: 4.398

Review 7.  Bisphosphonates: a review of their pharmacokinetic properties.

Authors:  J H Lin
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

Review 8.  Bisphosphonates: mechanism of action and role in clinical practice.

Authors:  Matthew T Drake; Bart L Clarke; Suneep Khosla
Journal:  Mayo Clin Proc       Date:  2008-09       Impact factor: 7.616

9.  Osteoblast proliferation and maturation by bisphosphonates.

Authors:  Gun-Il Im; Sheeraz A Qureshi; Jennifer Kenney; Harry E Rubash; Arun S Shanbhag
Journal:  Biomaterials       Date:  2004-08       Impact factor: 12.479

10.  Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo.

Authors:  Anke J Roelofs; Fraser P Coxon; Frank H Ebetino; Mark W Lundy; Zachary J Henneman; George H Nancollas; Shuting Sun; Katarzyna M Blazewska; Joy Lynn F Bala; Boris A Kashemirov; Aysha B Khalid; Charles E McKenna; Michael J Rogers
Journal:  J Bone Miner Res       Date:  2010-03       Impact factor: 6.741

View more
  12 in total

1.  Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone.

Authors:  Katherine M Powell; Cayla Skaggs; Alexis Pulliam; Alycia Berman; Matthew R Allen; Joseph M Wallace
Journal:  Bone       Date:  2019-06-21       Impact factor: 4.398

2.  Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model.

Authors:  Joseph E Perosky; Basma M Khoury; Terese N Jenks; Ferrous S Ward; Kai Cortright; Bethany Meyer; David K Barton; Benjamin P Sinder; Joan C Marini; Michelle S Caird; Kenneth M Kozloff
Journal:  Bone       Date:  2016-09-15       Impact factor: 4.398

3.  Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta.

Authors:  A C Apolinário; P T Figueiredo; A T Guimarães; A C Acevedo; L C Castro; A P Paula; L M Paula; N S Melo; A F Leite
Journal:  J Dent Res       Date:  2015-01-21       Impact factor: 6.116

4.  A Subtrochanteric Femoral Stress Fracture following Bisphosphonate Treatment in an Adolescent Girl.

Authors:  Alison M Boyce; Michael T Collins; Laura L Tosi; Rachel I Gafni
Journal:  Horm Res Paediatr       Date:  2016-07-06       Impact factor: 2.852

Review 5.  Rare bone diseases and their dental, oral, and craniofacial manifestations.

Authors:  B L Foster; M S Ramnitz; R I Gafni; A B Burke; A M Boyce; J S Lee; J T Wright; S O Akintoye; M J Somerman; M T Collins
Journal:  J Dent Res       Date:  2014-04-03       Impact factor: 6.116

Review 6.  Developments in rare bone diseases and mineral disorders.

Authors:  Siobhan Bacon; Rachel Crowley
Journal:  Ther Adv Chronic Dis       Date:  2017-11-24       Impact factor: 5.091

Review 7.  Recent developments in osteogenesis imperfecta.

Authors:  Joseph L Shaker; Carolyne Albert; Jessica Fritz; Gerald Harris
Journal:  F1000Res       Date:  2015-09-07

8.  Femoral neck fractures in osteogenesis imperfecta treated with bisphosphonates.

Authors:  M C Papanna; S Tafazal; M J Bell; S N Giles; J A Fernandes
Journal:  J Child Orthop       Date:  2017-06-01       Impact factor: 1.548

Review 9.  Genetic Risk Factors for Atypical Femoral Fractures (AFFs): A Systematic Review.

Authors:  Hanh H Nguyen; Denise M van de Laarschot; Annemieke JMH Verkerk; Frances Milat; M Carola Zillikens; Peter R Ebeling
Journal:  JBMR Plus       Date:  2018-01-03

10.  Incidence and treatment of femur fractures in adults with osteogenesis imperfecta: an analysis of an expert clinic of 216 patients.

Authors:  Wouter Alexander Goudriaan; Gerrit Jan Harsevoort; Marije van Leeuwen; Antonius Adrianus Franken; Guus Johannes Maria Janus
Journal:  Eur J Trauma Emerg Surg       Date:  2018-09-22       Impact factor: 3.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.